... 70.
Adverse effects on
human health and the
environment from
substances of very high
concern should be prevented through the
application of appropriate
risk management measures to ensure that any
risks from the uses of a
substance are adequately controlled, and with a
view to progressively substituting these
substances with a suitable safer
substance.
Risk management measures should be applied to ensure, when
substances are
manufactured, placed on the
market and used, that
exposure to these
substances including discharges,
emissions and losses, throughout the whole
life-cycle is below the
threshold level beyond which
adverse effects may occur. For any
substance for which authorisation has been
granted, and for any other
substance for which it is not possible to
establish a
safe level of
exposure,
measures should always be taken to minimise, as far as technically and practically possible,
exposure and
emissions with a
view to minimising the likelihood of
adverse effects.
Measures to ensure adequate
control should be
identified in any
Chemical Safety Report. These
measures should be applied and, where appropriate, recommended to other
actors down the
supply chain. ...
ARTICLE-10: Information to be submitted for general registration purposes [
go to this ARTICLE]
ARTICLE-13: General requirements for generation of information on intrinsic properties of substances [
go to this ARTICLE]
ARTICLE-14: Chemical safety report and duty to apply and recommend risk reduction measures [
go to this ARTICLE]
ARTICLE-17: Registration of on-site isolated intermediates [
go to this ARTICLE]
ARTICLE-18: Registration of transported isolated intermediates [
go to this ARTICLE]
ARTICLE-22: Further duties of registrants [
go to this ARTICLE]
ARTICLE-27: Sharing of existing data in the case of registered substances [
go to this ARTICLE]
ARTICLE-30: Sharing of data involving tests [
go to this ARTICLE]
ARTICLE-31: Requirements for Safety Data Sheets [
go to this ARTICLE]
ARTICLE-37: Downstream user chemical safety assessments and duty to identify, apply and recommend risk reduction measures [
go to this ARTICLE]
ARTICLE-38: Obligation for downstream users to report information [
go to this ARTICLE]
ARTICLE-40: Examination of testing proposals [
go to this ARTICLE]
ARTICLE-41: Compliance check of registrations [
go to this ARTICLE]
ARTICLE-43: Procedure and time periods for examination of testing proposals [
go to this ARTICLE]
ARTICLE-50: Registrants' and downstream users' rights [
go to this ARTICLE]
ARTICLE-53: Cost sharing for tests without an agreement between registrants and/or downstream users [
go to this ARTICLE]
ARTICLE-54: Publication of information on evaluation [
go to this ARTICLE]
ARTICLE-60: Granting of authorisations [
go to this ARTICLE]
ARTICLE-61: Review of authorisations [
go to this ARTICLE]
... 1. Authorisations
granted in
accordance with
Article 60 shall be regarded as
valid until the
Commission decides to
amend or
withdraw the authorisation in the
context of a
review, provided that the holder of the authorisation submits a
review report at least 18
months before the
expiry of the
time-limited
review period. Rather than re-submitting all elements of the
original application for the current authorisation, the holder of an authorisation may submit only the
number of the current authorisation,
subject to the second, third and fourth subparagraphs. A holder of an authorisation
granted in
accordance with
Article 60 shall submit an update of the
analysis of alternatives referred to in
Article 62(4)(e),
including information about any
relevant research and
development activities by the
applicant, if appropriate, and any substitution
plan submitted under
Article 62(4)(f). If the update of the
analysis of alternatives shows that there is a suitable alternative available taking into
account the elements in
Article 60(5), he shall submit a substitution
plan,
including a timetable for proposed
actions by the
applicant. If the holder cannot demonstrate that the
risk is adequately controlled, he shall also submit an update of the
socio-economic analysis contained in the
original application. If he can now demonstrate that the
risk is adequately controlled, he shall submit an update of the
chemical safety report. If any other elements of the
original application have changed, he shall also submit updates of these element(s). When any updated
information is submitted in
accordance with this paragraph, any
decision to
amend or
withdraw the authorisation in the
context of the
review shall be taken in
accordance with the
procedure referred to in
Article 64 applied
mutatis mutandis. ...
... 1. Authorisations
granted in
accordance with
Article 60 shall be regarded as
valid until the
Commission decides to
amend or
withdraw the authorisation in the
context of a
review, provided that the holder of the authorisation submits a
review report at least 18
months before the
expiry of the
time-limited
review period. Rather than re-submitting all elements of the
original application for the current authorisation, the holder of an authorisation may submit only the
number of the current authorisation,
subject to the second, third and fourth subparagraphs. A holder of an authorisation
granted in
accordance with
Article 60 shall submit an update of the
analysis of alternatives referred to in
Article 62(4)(e),
including information about any
relevant research and
development activities by the
applicant, if appropriate, and any substitution
plan submitted under
Article 62(4)(f). If the update of the
analysis of alternatives shows that there is a suitable alternative available taking into
account the elements in
Article 60(5), he shall submit a substitution
plan,
including a timetable for proposed
actions by the
applicant. If the holder cannot demonstrate that the
risk is adequately controlled, he shall also submit an update of the
socio-economic analysis contained in the
original application. If he can now demonstrate that the
risk is adequately controlled, he shall submit an update of the
chemical safety report. If any other elements of the
original application have changed, he shall also submit updates of these element(s). When any updated
information is submitted in
accordance with this paragraph, any
decision to
amend or
withdraw the authorisation in the
context of the
review shall be taken in
accordance with the
procedure referred to in
Article 64 applied
mutatis mutandis. ...
ARTICLE-62: Applications for authorisations [
go to this ARTICLE]
ARTICLE-69: Preparation of a proposal [
go to this ARTICLE]
... 4. If a
Member State considers that the
manufacture, placing on the
market or use of a
substance on its own, in a
preparation or in an
article poses a
risk to
human health or the
environment that is not adequately controlled and needs to be addressed it shall notify the
Agency that it
proposes to prepare a
dossier which conforms to the
requirements of the
relevant sections of Annex XV. If the
substance is not on the
list maintained by the
Agency referred to in paragraph 5 of this
Article, the
Member State shall prepare a
dossier which conforms to the
requirements of Annex XV within 12
months of the
notification to the
Agency. If this
dossier demonstrates that
action on a
Community-
wide basis is necessary, beyond any
measures already in
place, the
Member State shall submit it to the
Agency in the format outlined in Annex XV, in
order to initiate the
restrictions process. The
Agency or
Member States shall refer to any
dossier,
chemical safety report or
risk assessment submitted to the
Agency or
Member State under this
Regulation. The
Agency or
Member States shall also refer to any
relevant risk assessment submitted for the
purposes of other
Community Regulations or Directives. To this end other
bodies, such as
agencies,
established under
Community law and carrying out a similar task shall provide
information to the
Agency or
Member State concerned on
request. The
Committee for
Risk Assessment and the
Committee for
Socio-economic Analysis shall check whether the
dossier submitted conforms to the
requirements of Annex XV. Within 30
days of
receipt, the respective
Committee shall inform the
Agency or the
Member State suggesting
restrictions, as to whether the
dossier conforms. If the
dossier does not conform, the
reasons shall be given to the
Agency or the
Member State in
writing within 45
days of
receipt. The
Agency or the
Member State shall bring the
dossier into
conformity within 60
days of the
date of receipt of the
reasons from the
Committees, otherwise the
procedure under this
Chapter shall be terminated. The
Agency shall
publish without
delay the
intention of the
Commission or of a
Member State to instigate a
restriction procedure for a
substance and shall inform those who submitted a
registration for that
substance. ...
ARTICLE-78: Powers of the Management Board [
go to this ARTICLE]
ARTICLE-83: Duties and powers of the Executive Director [
go to this ARTICLE]
... The
Executive Director shall, following
approval by the
Management Board, forward the
work programme for the coming
year and the multi-
annual work programme to the
Member States, the
European Parliament, the
Council and the
Commission, and shall have them
published. The
Executive Director shall, following
approval by the
Management Board, forward the
Agency's
general report to the
Member States, the
European Parliament, the
Council, the
Commission, the
European Economic and Social Committee and the
Court of Auditors, and shall have it
published. ...
ARTICLE-97: Implementation of the budget of the Agency [
go to this ARTICLE]
... Report ...